Understanding genetic risks in acute myeloid leukemia based on ancestry
Towards an inclusive genomic risk classification for acute myeloid leukemia (AML)
This study is looking at how your genetic background might affect your risk of getting acute myeloid leukemia and how well different treatments work for you, so we can better understand and help everyone, no matter their ancestry.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project ID | NIH-10930899 on NIH RePORTER |
What this research studies
This research investigates how genetic factors related to ancestry influence the risk and treatment outcomes for acute myeloid leukemia (AML). By analyzing genomic data from diverse populations, the study aims to identify specific genetic mutations that may affect prognosis and treatment responses differently based on a patient's ancestry. The approach includes extensive genomic analysis and statistical modeling to refine risk classifications for AML, ensuring they are inclusive and representative of all populations. Patients may be involved in providing genetic samples and clinical data to support this important work.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with acute myeloid leukemia, particularly those from diverse ancestral backgrounds.
Not a fit: Patients with other types of leukemia or those who do not have a genetic component to their AML may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more personalized and effective treatment strategies for AML patients based on their genetic background.
How similar studies have performed: Previous research has shown that ancestry can significantly impact genetic risk factors in various cancers, suggesting that this approach may yield valuable insights for AML as well.
Where this research is happening
Columbus, UNITED STATES
- Ohio State University — Columbus, United States (Active)
Researchers
- Principal investigator: Eisfeld, Ann-Kathrin — Ohio State University
- Study coordinator: Eisfeld, Ann-Kathrin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.